MAPK1 and cancer: Regorafenib is an oral multi-targeted tyrosine kinase inhibitor, which inhibits angiogenic, and oncogenic receptor tyrosine kinases, as well as the RAF/MEK/ERK signaling pathway in cancer [29,45,46].